Stemline Therapeutics (STML) Receives a Buy from H.C. Wainwright

By Carrie Williams

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics (STMLResearch Report) today and set a price target of $35.00. The company’s shares closed last Monday at $9.25, close to its 52-week low of $7.82.

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -16.0% and a 30.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Currently, the analyst consensus on Stemline Therapeutics is a Moderate Buy with an average price target of $35.00, implying a 255.0% upside from current levels. In a report issued on October 29, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.22 and a one-year low of $7.82. Currently, Stemline Therapeutics has an average volume of 656.2K.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STML in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.